Photo of Waleed A. Hassen

Waleed A. Hassen

  • ADJUNCT ASSISTANT PROFESSOR Urology
Print ProfilePrint Profile

Biography

    Waleed A. Hassen, M.D., has been appointed Assistant Professor in Urology. Specializing in minimally invasive urologic oncology procedures, Dr. Hassen received his medical degree from Eastern Virginia Medical School and then completed his residency at Mount Sinai. He also completed two fellowships at Memorial Sloan-Kettering Cancer Center, one in urologic oncology and another in minimally invasive surgery, specializing in urologic procedures such as laparoscopic radical prostatectomies and laparoscopic nephrectomies. His research and clinical interests focus on prostate and kidney cancers.

Awards

  • -
    Alpha Omega Alpha

  • 2000 -
    Pfizer Scholar in Urology

  • 1999 -
    Annual F. Valentine Resident essay contest, New York, NY

  • 1994 -
    American Foundation for Urologic Disease
    Summer Student Research Fellowship

Research

New topic

Laparoscopic Surgery

Renal Cancer

 

New topic

Gene Therapy

New topic

Prostate Cancer

Publications

Lazendorf SE, Hassen WA. Cytoplasmic sperm injection. Seminars in Reproductive Endocrinology 1993; 11: 95-100.

Toth TL, Lanzendorf SE, Sandow BA, Veeck LL, Hassen WA, Hansen K, Hodgen GD. Cryopreservation of human prophase I oocytes collected from unstimulated follicles. Fertility and Sterility 1994; 61: 1077-1082.

Lynch DF, Hassen W, Clements MA, Schellhammer PF, Wright GL. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 1997; 32: 214-220.

Landman J, Lento P, Hassen W, Unger P, Waterhouse R. Feasibility of pathological evaluation of morcellated kidneys after radical nephrectomies. J Urol 2000; 164: 2086-2089.

Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer. Curr Opin. Urol 2000; 10: 291-299.

Hassen W, Sanford MA, Woo SC, Chen SH, Hall SJ. prospects for HSV-TK and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J Urol 2000; 18: 130-135.

Sanford MA, Yan Y, Hassen W, Selleck WA, Atkinson G, Chen SH, Hall SJ. Independent contributions of gr-1+leukocytes and fas/fasl interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther 2001; 12: 1485-1498.

Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA, Chen SH. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther 2002 Apr; 9(8): 511-512.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr.Hassen is not currently required to report Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central